Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 5.


Bonanno, Patricia Vella, Ermisch, Michael, Godman, Brian ORCID: 0000-0001-6539-6972, Martin, Antony P ORCID: 0000-0003-4383-6038, Van den Bergh, Jesper, Bezmelnitsyna, Liudmila, Bucsics, Anna, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz
et al (show 28 more authors) (2017) Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. FRONTIERS IN PHARMACOLOGY, 8.


Ermisch, Michael, Bucsics, Anna, Bonanno, Patricia Vella, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Furst, Jurij, Garuoliene, Kristina
et al (show 21 more authors) (2016) Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. FRONTIERS IN PHARMACOLOGY, 7.


Godman, Brian, Hill, Andrew, Simoens, Steven, Selke, Gisbert, Selke Krulichova, Iva, Zampirolli Dias, Carolina, Martin, Antony P ORCID: 0000-0003-4383-6038, Oortwijn, Wija, Timoney, Angela, Gustafsson, Lars L
et al (show 40 more authors) (2021) Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 21 (4). 527 - 540.


Godman, Brian ORCID: 0000-0001-6539-6972, Hill, Andrew, Simoens, Steven, Kurdi, Amanj, Gulbinovič, Jolanta, Martin, Antony P ORCID: 0000-0003-4383-6038, Timoney, Angela, Gotham, Dzintars, Wale, Janet, Bochenek, Tomasz
et al (show 38 more authors) (2019) Pricing of oral generic cancer medicines in 25 European countries; findings and implications. Generics and Biosimilars Initiative Journal, 8 (2). 49 - 70.


Pontes, Caridad, Zara, Corinne, Torrent-Farnell, Josep, Obach, Merce, Nadal, Cristina, Vella-Bonanno, Patricia, Ermisch, Michael, Simoens, Steven, Hauegen, Renata Curi, Gulbinovic, Jolanta
et al (show 13 more authors) (2020) Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 18 (1). 5 - 16.

This list was generated on Sun Aug 7 04:39:28 2022 BST.